FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma

Salah-Eddin Al-Batran, Martin H. Schuler, Zanete Zvirbule, Georgiy Manikhas, Florian Lordick, Andriy Rusyn, Yuriy Vynnyk, Ihor Vynnychenko, Natalia Fadeeva, Marina

Read more

Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18

Richard S. FinnEmail author, John P. Crown, Johannes Ettl, Marcus Schmidt, Igor M. Bondarenko, Istvan Lang, Tamas Pinter, Katalin Boer, Ravindranath Patel, Sophia Randolph, Sindy T. Kim, Xin Huang, Patrick Schnell, Sashi Nadanaciva, Cynthia Huang Bartlett and Dennis J. Slamon Breast Cancer

Read more
Страница 1 из 3123
SOCIALICON
SOCIALICON
Facebook
Google+
Twitter
YouTube